Multidrug-resistant bacteria with ESBL genes: a growing threat among people living with HIV/AIDS in Nepal

Riju Maharjan¹, Anup Bastola², Nabaraj Adhikari¹, Komal Raj Rijal¹, Megha Raj Banjara¹, Prakash Ghimire¹ and Upendra Thapa Shrestha¹*

Abstract

Background: Bacterial opportunistic infections are common in people living with HIV/AIDS (PLHA). Besides HIV-TB co-infection, lower respiratory tract infections (LRTIs) due to multidrug-resistant (MDR) bacteria cause significant morbidity and mortality among PLHA. This study identified bacterial co-infection of the lower respiratory tract and detected plasmid-mediated \textit{bla}\textsubscript{TEM} and \textit{bla}\textsubscript{CTX-M} genes among Extended-Spectrum β-Lactamase (ESBL) producing isolates from sputum samples in PLHA.

Methods: A total of 263 PLHA with LRTIs were enrolled in this study, out of which, 50 were smokers, 70 had previous pulmonary tuberculosis, and 21 had CD4 count < 200 cells/µl. Sputum samples collected from PLHA were processed with standard microbiological methods to identify the possible bacterial pathogens. The identified bacterial isolates were assessed for antibiotic susceptibility pattern using modified Kirby Bauer disk diffusion method following Clinical Laboratory Standard Institute (CLSI) guidelines. In addition, plasmid DNA was extracted from MDR and ESBL producers for screening of ESBL genes; \textit{bla}\textsubscript{CTX-M} and \textit{bla}\textsubscript{TEM} by conventional PCR method using specific primers.

Results: Of 263 sputum samples, 67 (25.48%) showed bacterial growth. Among different bacterial pathogens, \textit{Klebsiella pneumoniae}, (17; 25.37%) was the most predominant, followed by \textit{Haemophilus influenzae}, (14; 20.90%) and \textit{Escherichia coli}, (12; 17.91%). A higher infection rate (4/8; 50%) was observed among people aged 61–70 years, whereas no infection was observed below 20 years. About 30.0% (15/50) of smokers, 32.86% (23/70) cases with previous pulmonary tuberculosis, and 52.38% (11/21) with CD4 count < 200 cells/µl had bacterial LRTIs. Among 53 bacterial isolates excluding \textit{H. influenzae}, 28 isolates were MDR and 23 were ESBL producers. All ESBL producers were sensitive to colistin and polymyxin B. Among ESBL producers, 47.83% (11/23) possessed \textit{bla}\textsubscript{CTX-M}, 8.6% (2/23) were positive for \textit{bla}\textsubscript{TEM} gene, and 43.48% (10/23) possessed both ESBL genes.

Conclusion: The increasing rate of MDR bacterial infections, mainly ESBL producers of LRTIs causes difficulty in disease management, leading to high morbidity and mortality of PLHA. Hence, it is crucial to know the antibiogram pattern of the isolates to recommend effective antimicrobial therapy to treat LRTIs in PLHA.

Keywords: PLHA, Lower respiratory tract infection, ESBL, \textit{Bla}\textsubscript{CTX-M}, \textit{Bla}\textsubscript{TEM}

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
AIDS-related infections every year due to a lack of prevention. Other than Mycobacterium tuberculosis, bacterial lower respiratory tract infections (LRTIs) are common opportunistic infections, followed by parasitic and viral infections in PLHA [4]. Similarly, 19,410 PLHA are currently receiving antiretroviral therapy (ART) globally, the secondary infections by fungi, bacteria, parasites and other viruses have not reduced as expected. Bacterial and fungal infections are common opportunistic infections, followed by parasitic and viral infections in PLHA [4].

In the context of Nepal, 2000–3000 people die of AIDS-related deaths are declining in Nepal because of improved access to ART with 80 ART sites and 20 ART dispensing centers in 61 districts. Among the HIV-related deaths, the primary cause is advanced HIV disease (60.6%), followed by tuberculosis (22.7%). However, bacterial lower respiratory tract infections (LRTIs) other than Mycobacterium tuberculosis cannot be avoided in PLHA. The third important cause of death among PLHA is pneumonia (4.2%). Klebsiella pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Acinetobacter spp, Escherichia coli are some common bacterial pathogens causing LRTIs in PLHA [5, 6]. The development of antimicrobial resistance to commonly prescribed antibiotics among those bacterial pathogens is a matter of concern nowadays due to the increase in the ineffectiveness of antibiotic therapy in PLHA [7].

In the context of Nepal, 2000–3000 people die of AIDS-related infections every year due to a lack of effective treatment and care [2]. In most developing countries, the lack of proper diagnosis and treatment of secondary bacterial infection is deteriorating the quality of life of PLHA. However, very few studies have documented such infections and their impacts on PLHA in Nepal. Hence, this study focused on identifying potential bacterial pathogens of LRTIs among PLHA and their antibiogram phenotypically and genotypically. Moreover, we also evaluated the efficacy of co-trimoxazole, a WHO-recommended broad-spectrum antibiotic, in the treatment of pneumonia in PLHA. Finally we recommend a few potential antimicrobial agents for treating LRTIs among those patients.

**Methods**

**Study design, site and duration**

A hospital-based prospective cross-sectional study was conducted in Antiretroviral Treatment (ART) center of Sukraraj Tropical and Infectious Disease Hospital, one of the tertiary care hospitals with 100 beds capacity in Kathmandu, Nepal from February to August 2019. The hospital was the first to start ART service in Nepal in 2004. Around 4200–4500 PLHA visit the ART center for therapy annually. Sample collection from the participants and processing were done in the same hospital. In addition, further processing of plasmid DNA extraction and gene detection were done in the Central Department of Microbiology, Tribhuvan University, Kathmandu.

**Inclusion and exclusion criteria**

All age groups of both sexes living with HIV, under ART and with LRTIs confirmed by a physician after physical examination, blood investigations including CBC and chest x-ray, were enrolled in this study. Sputum samples and the demographic information from the participants were collected only after obtaining written consent. However, the patients infected with tuberculosis were excluded from the study.

**Sample size**

The calculated sample size was 255 based on the 21% prevalence rate of bacterial LRTIs in PLHA as reported by Kandati et al. [8]. Therefore, for this study, 263 sputum samples were collected.

**Sample collection, transportation and processing**

Sputum sample were collected from the participants using sterile vials with a wide mouth and tight lid. Participants were instructed first to take a deep breath and then to expectorate a cough [9]. The collected sputum samples were transported to the Microbiology laboratory for further processing. The quality of sputum was checked macroscopically for the presence of mucopurulent part before accepting the sample.

**Sputum culture**

Mucopurulent sputum was cultured on MacConkey Agar (MA), Blood Agar (BA), and Chocolate Agar (along with 10-unit bacitracin disk) and incubated at 37 °C for 24 h. Incubated plates were examined for the presence of distinct colonies, and identification was made using standard microbiological protocols, including their colony morphology on different culture media, microscopically by Gram staining and various biochemical tests [9].

For identification of *H. influenzae*, a satellitism test was performed. A loopful of suspected colonies were inoculated into the center of MA plate while a loopful of co-trimoxazole (CTM) in 0.01% peptone water was added to the edge of the plate. A clear zone of inhibition around the loopful of CTM indicated the satellitism property of the sputum sample, which was further confirmed by biochemical testing.
of *H. influenzae* was mixed in about 2 ml of sterile physiological saline. Using a sterile swab stick, the bacterial suspension was inoculated on a plate of blood agar, and a pure culture of *S. aureus* was streaked across the inoculated blood agar plate. It was then incubated in a CO₂ enriched atmosphere at 35–37 °C for 18–24 h. The culture plate was examined for growth and satellite colonies [9].

**Antibiotics susceptibility test**
Out of 67 bacterial isolates from sputum culture, only 53 isolates excluding *H. influenzae* (n = 14) were processed further. Antibiotic susceptibility patterns of those organisms were performed using the modified Kirby Bauer disk diffusion method recommended by CLSI 2019 [10]. The antibiotics used were amoxicillin (10 µg), amoxicillin-clavulanic acid (AMC, 20/10 mcg), cefepime (CPM, 30mcg), ceftazidime (CTZ, 30 mcg), ceftriaxone (CTR, 30 mcg), chloramphenicol (C, 30 mcg), ciprofloxacin (CIP, 5 mcg), colistin (CL 10 mcg), co-trimoxazole (COT, 25 mcg), gentamycin (GEN, 10 mcg), imipenem (IMP, 10 mcg), piperacillin/tazobactam (PIT, 100/10 mcg), polymyxin-B (PB, 300 units) and tetracycline (TET, 30 mcg). The isolates resistant to at least one agent in ≥ 3 antimicrobial categories were considered MDR [11]. Subsequently, the prevalence of MDR bacteria was determined.

**Screening and confirmation of extended-spectrum β-lactamase (ESBL)**
The isolates resistant to antibiotics—ceftazidime (30 µg) or ceftriaxone (30 µg) were considered as potential ESBL producers. The confirmatory test was performed by double disk diffusion method using ceftazidime and ceftazidime clavulanic acid. More than 5 mm zone of diameter around ceftazidime-clavulanic acid disc than ceftazidime disc alone was confirmed an ESBL producer [10].

**Detection of metallo β-lactamase (MBL)**
Two imipenem discs were placed on an MHA plate inoculated with a test organism (bacterial density equivalent to 0.5 McFarland Standard). A 5 µl of EDTA (0.5 M, pH = 8.0) solution was added to one of the imipenem discs and incubated for 16–18 h at 37 °C. An increased zone of diameter (>7 mm) around the imipenem and EDTA disc than the imipenem alone was confirmed MBL positive [10].

**Bacterial plasmid DNA extraction**
Plasmid DNA from MDR isolates was extracted by the alkaline lysis method followed by purification with phenol–chloroform. The isolated plasmid DNAs were visualized on 0.8% agarose gel electrophoresis with 0.2 µg/ml concentration of ethidium bromide as described by Sambrook, 1989 and Thapa Shrestha and Adhikari 2014 [12, 13].

**Molecular detection of bla<sub>CTX-M</sub> and bla<sub>TEM</sub> gene**
A set of primers for each gene was selected from the previous studies and verified on NCBI BLAST. A set of primers (Forward: 5′-TTTGCAGTGTCAGTACCAGTAA-3′ and reverse: 5′-CTCCGCCTGCCGGTTTTAT-3′) as described in Edelsteint et al. [14] were used for amplification of bla<sub>CTX-M</sub> gene. Similarly, a set of primers (Forward: 5′-GAGACAATAAGGGTGGTAAT-3′ and reverse: 5′-AGAGTTAGGGCAGCACTG-3′) as mentioned in Sharma et al. 2013 were used to amplify bla<sub>TEM</sub> gene [15]. A conventional PCR was used to amplify the bla<sub>TEM</sub> and bla<sub>CTX-M</sub> genes. A PCR reaction mixture was prepared containing 12.5 µl master mix (Qiagen), 0.5 µl of each primer, 3 µl template DNA and 8.5 µl PCR grade water [14]. PCR amplification was run at initial denaturation of 95 °C for 15 min; followed by 35 cycles of denaturation at 94 °C for 45 s, annealing at 55 °C for bla<sub>TEM</sub> genes and 56 °C for the bla<sub>CTX-M</sub> gene for 30 s, extension at 72 °C for 3 min and a final extension at 72 °C for 10 min. The PCR products were analyzed on 1.5% agarose gel electrophoresis with 0.2 µg/ml concentration of ethidium bromide and visualized under UV transilluminator.

**Quality control**
Control strain of *E. coli* (ATCC 25922) and *P. aeruginosa* (ATCC 27853) were used as positive controls for ESBL and MBL producing strains, respectively. For PCR, a previously harvested plasmid DNA containing target genes were used as positive control and nuclease-free water as negative control.

**Data management and analysis**
All data collected were analyzed using SPSS-21 software. The Chi-square test was used to assess the association of different variables. p-value < 0.05 was considered as significant.

**Results**
Mode of transmission of HIV among study participants: Among 263 PLHA, 145 (55.13%) were male, and 118 (44.87%) were female. Heterosexual activities were the most dominant transmission route (78.33%), whereas the least transmission rate, 0.76% (n = 2), was observed cia a vertical route from mother to infants (Fig. 1).

Bacterial growth according to age and gender of participants: Overall, 67 (25.48%) sputum samples were positive for bacterial growth. The bacterial infection of LRT was found highest (50%) in the age group 61–70 years, followed by 40% (n = 10) among the males aged
51–60 years. No infection was observed among participants below 20 years (Table 1).

**Bacterial co-infection and predisposing factors:** Bacterial infection was significantly higher ($p=0.02$) among participants with CD4 count < 200 cells/µl. Similarly, bacterial infections were higher among smokers and those with a history of pulmonary tuberculosis, but the data was not statistically significant (Table 2).

**Bacterial infection based on their literacy and occupation:** Most samples (43.3%) were from PLHA who had completed their primary level education. The bacterial infection was found higher among literate people as compared to illiterate PLHA. Likewise, bacterial infection was higher (30%) among business people followed by office workers (26.6%) (Table 3).

**Frequency of bacterial pathogens from LRT infections:** Of 67 Gram negative bacterial isolates, *K. pneumoniae* was the most predominant bacteria followed by *H. influenzae* (Fig. 2).

**Antibiotic susceptibility pattern:** All isolated strains of *K. pneumoniae* and *K. oxytoca* were resistant to amoxicillin, whereas all of them were sensitive to colistin and polymyxin B. Of 12 isolates of *E. coli*, 10 (83.33%) were resistant to amoxicillin, and 9 (75%) were resistant to third-generation cephalosporins. Similarly, nearly 90% of *E. aerogenes* (8/9) were resistant to amoxicillin. All isolates of *C. freundii* were resistant to amoxicillin (Table 4).

---

**Table 1** Age and sex-wise distribution of Microbial growth

| Age group (years) | Male | Female |
|-------------------|------|--------|
|                   | No. of sample | Growth (%) | No. of sample | Growth (%) | Total number (growth %) |
| Below 20          | 3 | 0 | 1 | 0 | 4 (0) |
| 21–30             | 29 | 8 (27.59) | 20 | 5 (25) | 49 (26.53) |
| 31–40             | 40 | 9 (22.5) | 52 | 12 (23.08) | 92 (22.83) |
| 41–50             | 42 | 10 (23.81) | 32 | 10 (31.25) | 74 (27.03) |
| 51–60             | 25 | 10 (40) | 11 | 1 (9.09) | 36 (50) |
| 61–70             | 6 | 3 (50) | 2 | 1 (50) | 8 (50) |
| Total             | 145 | 40 (27.59) | 118 | 27 (22.88) | 263 (25.48) |

---

**Table 2** Relation bacterial infection with predisposing factors

| Predisposing factors | Status of predisposing factors | Bacterial Growth | Total | p-value |
|----------------------|--------------------------------|------------------|-------|---------|
|                      |                                | Negative (%)     | Positive (%) |       |
| CD4 count cells/µl   | <200                           | 10 (47.62)       | 11 (52.38) | 21 | 0.02 |
|                      | 200–499                        | 56 (60.22)       | 37 (39.78) | 93 |
|                      | >500                           | 130 (87.25)      | 19 (12.75) | 149 |
| Total                |                                | 196 (74.52)      | 67 (25.48) | 263 |
| Smoking habit        | Non-smoker                     | 117 (77.48)      | 34 (22.52) | 151 | >0.05 |
|                      | Smoker                         | 35 (70)          | 15 (30)   | 50 |
|                      | Previous smoker                | 44 (70.97)       | 18 (29.03) | 62 |
| Total                |                                | 196 (74.52)      | 67 (25.48) | 263 |
| History of PTB       | No cases                       | 149 (77.20)      | 44 (22.80) | 193 | >0.05 |
|                      | Cases                          | 47 (67.14)       | 23 (32.86) | 70 |
| Total                |                                | 196 (74.52)      | 67 (25.48) | 263 |
Besides the intrinsic resistance of *P. aeruginosa* to many antibiotics, including amoxicillin, co-trimoxazole, ceftriaxone, ceftazidine, chloramphenicol, tetracycline, amoxicillin-clavulanic acid, piperacillin-tazobactam and 3 strains (75%) were also resistant to ofloxacin and cefepime. However, all strains were sensitive to gentamicin, ciprofloxacin, imipenem, amikacin, and colistin. Likewise, *Acinetobacter* spp were sensitive to gentamycin, imipenem, polymyxin B and colistin out of 14 antimicrobials used in our study.

**Multidrug-resistant (MDR) and extended-spectrum β-lactamase (ESBL) producing strains:** Out of 53 bacterial isolates, 28 (52.83%) were multidrug-resistant (MDR). All strains of *P. aeruginosa* and *Acinetobacter* spp were found to be MDR strains whereas no strain of *C. freundii* were MDR. Similarly, 75% (9/12) of *E. coli*, 64.71% (11/17) of *K. pneumoniae*, and 50% (2/4) of *K. oxytoca* were MDR strains.

A total of 23 (43.4%) isolates were ESBL producers, including 75% (9/12) *E. coli* and all isolates of *P. aeruginosa* and *Acinetobacter* spp. Of the total MDR strains, 72.73% (8/11) of *K. pneumoniae* and 50% (1/2) of *K. oxytoca* were ESBL producers. In addition, one strain of *P. aeruginosa* was found MBL producer.

**Detection of ESBL genes:** Of 53 isolates, 23 (43.4%) possessed ESBL genes. Among them, 11 (47.83%) harbored the *bla*<sub>CTX-M</sub> gene (Fig. 3) and 2 (8.69%) contained the *bla<sub>TEM</sub>* gene (Fig. 4). Similarly, ten isolates (43.48%) possessed both *bla<sub>TEM</sub>* and *bla<sub>CTX-M</sub>* genes in their plasmid DNA (Table 5).

**Discussion**

Among the different routes of HIV transmission, most participants in this study were infected through the heterosexual route (78.33%). Similar to this study, Chandwani et al. reported the highest transmission rate (95%)
via the heterosexual route [16]. Almost all female participants in our study were housewives and got HIV infections from their husbands. The least rate of transmission from mother to infants might be due to increased awareness on HIV-AIDS and wide coverage by ART, reducing the rate of transmission as recommended by WHO [1].

Of 263 samples processed, 67 (25.5%) were found culture positive. Similarly, KC et al. and Ojha et al. reported 24% and 46.6% of bacterial infections among PLHA, respectively, from tertiary care hospitals in Kathmandu [5, 6]. KC et al. reported a higher rate of fungal infection (42%) as compared to bacterial infection (24%) in the same hospital from August 2017 to March 2018 [6]. Likewise, Oja-Bola and Oluyege reported 55.6% of PLHA to be associated with pneumonia [7]. The comparatively lower rate of bacterial infections might be due to the co-trimoxazole prophylaxis which is recommended for people under ART by WHO [17]. In addition, PLHA having lower CD4 cells were given Isoniazid preventive treatment to prevent MTB [18, 19]. A relatively higher occurrence of LRTIs was observed in the old aged 61–70 years.

| Antibiotics used              | Number of resistant pathogens (%) | K. pneumonia (n = 17) | K. oxytoca (n = 4) | E. coli (n = 12) | E. aerogenes (n = 9) | C. frundii (n = 6) |
|------------------------------|----------------------------------|-----------------------|-------------------|------------------|---------------------|-------------------|
| Amoxicillin                  | 17 (100)                         | 4 (100)               | 10 (83.33)        | 8 (88.89)        | 6 (100)             |
| Cotrimoxazole                | 10 (58.82)                       | 2 (50)                | 8 (66.67)         | 1 (11.11)        | 0                   |
| Ceftiraxone                  | 9 (52.94)                        | 2 (50)                | 9 (75)            | 1 (11.11)        | 0                   |
| Ciprofloxacin                | 4 (23.53)                        | 1 (25)                | 7 (58.33)         | 1 (11.11)        | 0                   |
| Chloramphenicol              | 3 (17.65)                        | 0                     | 3 (25)            | 1 (11.11)        | 0                   |
| Gentamycin                   | 2 (11.76)                        | 0                     | 1 (8.33)          | 1 (11.11)        | 0                   |
| Tetracycline                 | 14 (82.35)                       | 3 (75)                | 7 (58.33)         | 3 (33.33)        | 3 (50)              |
| Ceftazidime                  | 9 (52.94)                        | 2 (50)                | 9 (75)            | 1 (11.11)        | 0                   |
| Amoxicillin-clavulanic acid | 10 (58.82)                       | 2 (50)                | 9 (75)            | 2 (22.22)        | 0                   |
| Piperacillin tazobactam      | 5 (29.41)                        | 1 (25)                | 7 (58.33)         | 1 (11.11)        | 0                   |
| Cefepime                     | 5 (29.41)                        | 1 (25)                | 5 (41.67)         | 1 (11.11)        | 0                   |
| Imipenem                     | 2 (11.76)                        | 0                     | 1 (8.33)          | 1 (11.11)        | 0                   |
| Polymyxin B                  | 0                                | 0                     | 0                 | 0                | 0                   |
| Colistin                     | 0                                | 0                     | 0                 | 0                | 0                   |

![Fig. 3](image-url) Amplification of bla<sub>CTM</sub> gene (Lane 1 and 9; DNA marker (100 bp), Lane 2; NC (Negative control), Lane 3; PC (Positive control) and Lane 4–8; gene amplification from isolates) (The photo has been cropped to clearly show the bands of bla<sub>CTM</sub> gene, the original photo can be submitted as supplementary on request)

![Fig. 4](image-url) Amplification of bla<sub>TEM</sub> gene (Lane 1 and 9; DNA marker (100 bp), Lane 2; NC (Negative control), Lane 3; PC (Positive control) and Lane 4–8; gene amplification from isolates) (The photo has been cropped to clearly show the bands of bla<sub>TEM</sub> gene, the original photo can be submitted as supplementary on request)
Table 5 Detection of $ bla_{CTX-M} $ and $ bla_{TEM} $ ESBL genes among the isolates

| Isolates            | n   | Phenotypic ESBL | Genotypic ESBL | Number of amplified genes |
|---------------------|-----|----------------|----------------|----------------------------|
|                     |     |                |                | $ bla_{CTX-M} $ (%) | $ bla_{TEM} $ (%) | $ bla_{CTX-M} + \text{ ESBL} $ (%) |
| $ K. pneumoniae $   | 17  | 8 (47.06)      | 7 (41.18)      | 3 (42.86)               | 0               | 4 (57.14)               |
| $ K. oxytoca $      | 4   | 1 (25)         | 2 (50)         | 1 (50)                  | 0               | 1 (50)                  |
| $ E. coli $         | 12  | 9 (75)         | 9 (75)         | 3 (33.33)               | 2 (22.22)       | 4 (44.45)               |
| Acinetobacter spp   | 1   | 1 (100)        | 1 (100)        | 1 (100)                 | 0               | 0                       |
| $ E. aerogenes $    | 9   | 0              | 1 (11.11)      | 0                       | 0               | 1 (100)                 |
| C. frundii          | 6   | 0              | 0              | 0                       | 0               | 0                       |
| Total               | 53  | 23 (43.4)      | 23 (43.4)      | 11 (47.83)              | 2 (8.69)        | 10 (43.48)              |

as compared to other age groups (p-value 0.49). The weakness of the immune system with age makes PLHA vulnerable to different types of infections. Macfarlane et al. 1993 also reported the same [20]. No infection was reported in young participants of aged below 20. The infection rate was higher in male participants (27.5%) than female participants (22.8%).

Many predisposing factors are associated with bacterial co-infection in PLHA. A significantly higher rate of bacterial infection (39.8%) was observed in participants having CD4 count < 200 cells/µl as compared to the least infection in those with CD4 count > 500 cells/µl. Yadav and Prakash also observed a significantly higher rate of LRTIs (63.4%) among cases with a CD4 count < 200 cells/µl, followed by those within the 200–500 range category (53.1%) and least (18.7%) in that above 500 cells/µl [21]. The most important risk factor for bacterial pneumonia in PLHA is the degree of immuno-suppression reflected by the CD4+ T-lymphocyte count [22]. On the other hand, a slightly higher bacterial infection rate was observed in active smokers (p = 0.43). In contrast, Yadav and Prakash reported a significantly higher rate of LRTIs among smokers [21]. They also identified tobacco smoking as one of the most important risk factors contributing to Nepal’s higher prevalence of chronic bronchitis and chronic obstructive lung disease. Various mechanisms cause increasing susceptibility of smokers to different infections, including structural changes in the respiratory tract and decreased immune response [23].

Thirdly, bacterial infection in PLHA previously infected with pulmonary tuberculosis (PTB) were comparatively higher than those without a history of PTB (22.8%) (p = 0.06). Since PTB is a chronic lung disease and leaves patches, pulmonary nodules, or granuloma in the lungs, it might enhance the secondary bacterial infection [24]. Likewise, people who are more exposed to the external environment such as shopkeepers, carpenters, tourist guides, security guards, army, police, etc., were found more susceptible to LRTIs than other people involved in household activities. The reason might be due to exposure to the polluted outdoor environment.

Among 67 Gram-negative isolates, $ K. pneumoniae $ was the predominant one, followed by $ H. influenzae $ and $ E. coli $. Similar to this study, Jemal et al. found $ K. pneumoniae $ as the predominant one, accounting for 41.3% [25]. Few other studies have also reported $ K. pneumoniae $ as the predominant bacteria causing LRTIs among PLHA [5, 6]. In contrast, Oja-Bola and Oluyege reported $ E. coli $ (40%) as the most frequent organism, followed by $ P. aeruginosa $ (35%) and $ K. pneumoniae $ as the least (5%) isolated one [7]. $ K. pneumoniae $ can cause diseases in non-HIV people as well; however, pneumonia due to Klebsiella is classically thought to be community-acquired [6]. However, Mishra and the coworkers reported $ H. influenzae $ as the most predominant (21%) isolate in the sputum of PLHA [26]. $ H. influenzae $ associated pneumonia is highly associated with a high degree of immune suppression [27].

We found amoxicillin, tetracycline, and co-trimoxazole to be the least effective drugs against Gram-negative pathogens; however, WHO has recommended co-trimoxazole to treat pneumococcal disease in PLHA. This result was also supported by Oja-Bola and Oluyege [7]. They found only 20% of Klebsiella spp were sensitive towards co-trimoxazole. Similarly, Adeleye et al. reported co-trimoxazole to be resistant for LRT isolates in Nigeria [28]. The resistance towards trimethoprim-sulfamethoxazole might be due to the extensive use of co-trimoxazole by PLHA as their basic regimen for treating opportunistic bacterial infections. In the study, ESBL producing strains were resistant towards most of the antibiotics used except gentamycin, imipenem, polymyxin B and colistin, while non-ESBL producing isolates were sensitive towards all antibiotics except amoxicillin and tetracycline.
Plasmid-mediated ESBL producers are nowadays a matter of concern due to their capacity to hydrolyze 3rd and 4th generation cephalosporin and monobactams [29]. Decreased susceptibility of Gram-negative isolates towards 3rd and 4th generation cephalosporin could be attributed to ESBL or Amp-C beta-lactamase production. The most predominant ESBL producers were found to be *E. coli*, *P. aeruginosa* and *Acinetobacter* spp, followed by *K. pneumoniae* by the phenotypic method. Contrary to our result, KC et al. reported *K. pneumoniae* (80%) and *P. aeruginosa* (50%) as the two predominant species to produce ESBL from the same study site [6].

On amplifying the plasmid-mediated ESBL gene, 23 (43.3%) isolates gave a positive result. The two isolates that gave positive ESBL test phenotypically contained neither of the two genes. It might be due to the presence of ESBL genes other than targeted ones. This result is supported by those from de Oliveira et al. [30]. Another two isolates possessed ESBL genes but were phenotypically undetectable by combined disk test, highlighting the sensitivity of the genotypic method over the phenotypic method. Another reason might be a low level of ESBL gene expression. Gautam et al. also reported 40.8% of PCR-positive ESBL producers were phenotypically undetectable [31]. They also explained that phenotypic identification of ESBL was based on the inhibition of the enzyme by clavulanic acid, and the inhibitory action of clavulanic acid could be masked due to the coexistence of multiple enzymes. In addition, the co-existence of AmpC enzymes in ESBL producers may alter the pores of the cell membranes, resulting in reduced affinity for β-lactamase inhibitors for enzymes such as TEM and SHV. Hence, the production of different types of β-lactamases (TEM, SHV, CTX-M and OXA) by the same microorganism can lead to erroneous phenotypic conclusions.

As a significant study limitation, we couldn’t analyze the antibiotic susceptibility pattern of *H. influenzae* due to the lack of X and V factors in the hospital laboratory at the time of research. In addition, all possible ESBL genes were not detected because of the low budget and limited timeframe for the study. Instead, we observed a few antimicrobial agents such as gentamycin, imipenem, polymyxin B and colistin, that have higher effectiveness to inhibit all MDR and ESBL producing bacterial strains. These antimicrobial agents can be a choice of drugs for treating LRTIs in PLHA.

**Conclusion**

LRTIs other than PTB by MDR Gram-negative pathogens are common opportunistic infections deteriorating the quality of life of PLHA. Furthermore, the higher rate of resistance towards the WHO-recommended broad-spectrum antibiotic—co-trimoxazole and the presence of drug-resistant genes call for an alarm against the rampant use of antibiotics among PLHA.

**Abbreviations**

AIDS: Acquired immune deficiency syndrome; ATCC: American type culture collection; ART: Antiretroviral treatment; AST: Antibiotic susceptibility testing; BA: Blood agar; CA: Chocolate agar; CDC: Center for diseases control and prevention; CLSI: Clinical Laboratory Standard Institute; DOHS: Department of health service; ESBL: Extended spectrum β-lactamase; HIV: Human immuno-deficiency virus; LRTI: Lower respiratory tract infection; MA: Mac-Conkey agar; MBL: Metallo β-lactamase; MHA: Mueller hinton agar; DR: Multidrug resistance; min: Minute/s; PCR: Polymerase chain reaction; PLHA: People living with HIV-AIDS; PTB: Pulmonary tuberculosis; STIDHH: Sukraraj Tropical and Infectious Disease Hospital; WHO: World Health Organization.

**Acknowledgements**

We would like to express our sincere gratitude to all laboratory and technical staff, and participants at the Antiretroviral Treatment (ART) center, Sukraraj Tropical and Infectious Disease Hospital and Central Department of Microbiology, Tribhuvan University for their generous support throughout the research work. And we would also like to thank Dr. Manash Shrestha for his help on data analysis.

**Author contributions**

All authors have made substantial contributions to the conception of the study, methodology and interpretation of results obtained from the study. All authors have drafted the work and substantively revised it. All authors have approved and revised the submitted version of the manuscript and agreed to publish it. All authors read and approved the final manuscript.

**Funding**

This project did not receive any funding support for the research work and publishing.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request at upendrats@gmail.com.

**Declarations**

**Ethics approval and consent to participate**

The study was reviewed and approved by Nepal Health Research Council (NHRC). A copy of the information sheet and a consent form was given to the participants to obtain written consent before enrollment in the research and collecting samples. In addition, a local language-translated information sheet was read for illiterate participants. Informed consent was obtained from all the participants. In the case of children under 16 years, both written informed consent with assent was obtained from a parent or a local guardian attending the hospital along with the participant. All the methods were carried out in accordance with the principles stated in the Declaration of Helsinki.

**Consent for publication**

Not applicable.

**Competing interests**

We declare no competing interests.

**Author details**

1Central Department of Microbiology, Tribhuvan University, Kirtipur, Kathmandu, Nepal. 2Sukraraj Tropical and Infectious Disease Hospital, Teku, Kathmandu, Nepal.

**Received:** 22 November 2021   **Accepted:** 22 April 2022

**Published online:** 07 June 2022
